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The second scientiﬁc meeting in the series: “Anthelmintics: From Discovery to Resistance” was held in
San Diego in February, 2016. The focus topics of the meeting, related to anthelmintic discovery and
resistance, were novel technologies, bioinformatics, commercial interests, anthelmintic modes of action
and anthelmintic resistance. Basic scientiﬁc, human and veterinary interests were addressed in oral and
poster presentations. The delegates were from universities and industries in the US, Europe, Australia
and New Zealand. The papers were a great representation of the ﬁeld, and included the use of C. elegans
for lead discovery, mechanisms of anthelmintic resistance, nematode neuropeptides, proteases,
B. thuringiensis crystal protein, nicotinic receptors, emodepside, benzimidazoles, P-glycoproteins, natural
products, microﬂuidic techniques and bioinformatics approaches. The NIH also presented NIAID-speciﬁc
parasite genomic priorities and initiatives. From these papers we introduce below selected papers with a
focus on anthelmintic drug screening and development.
© 2016 Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
Conflict of interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 298
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 298This special issue of the International Journal for Parasitology:
Drugs and Drug Resistance (IJPDDR) contains papers that were
presented at a scientiﬁc meeting held in San Diego, entitled: ‘An-
thelmintics: Discovery to Resistance II,’ February 9the12th, 2016.
The meeting followed its predecessor: ‘Anthelmintics: Discovery to
Resistance’ that took place in San Francisco, in February, 2016
(Wolstenholme and Martin, 2014) and an earlier meeting on hel-
minth ion-channels in Philadelphia in December, 2011
(Wolstenholme, 2012). With this San Diego meeting we wanted to
continue the idea of bringing together biologists, pharmacologists,
veterinarians, physicians and discovery scientists from universities
and industry, who share interests in anthelmintic discovery and
resistance. We also wanted to foster the development and futures
of graduate students working in the area of anthelmintic research.half of Australian Society for ParaWe anticipated that we would attract around 80 delegates initially,
but eventually secured more than 100 delegates, which was an
important encouragement to all of us.
The meeting was held in the Marina Village Center in San Diego
which provided a very welcome sunny and warm location in
contrast to the winter cold which most delegates came. The loca-
tion and accommodation worked very well, allowing excellent
discussions between the different groups and interests. It was
possible to step outside for easy conversations along the shore. The
presentations were arranged into themes over four days: there
were 25 posters and 56 oral presentations.
In this special issue we have collected papers on anthelmintic
drug discovery for publication that were presented at the meeting.
The availability of public access drug and drug-like collections for
screening is illustrated in the paper of Preston et al. (2016) who
screened the Medicines for Malaria's ‘Pathogen Box’ to identify
tolfenpyrad, which has inhibitory effects on the motility of L3 andsitology. This is an open access article under the CC BY-NC-ND license (http://
R.J. Martin et al. / International Journal for Parasitology: Drugs and Drug Resistance 6 (2016) 297e298298L4 larvae of Haemonchus contortus.
The identiﬁcation and variability of anthelmintic drug targets
was a signiﬁcant topic for a number of papers. Bais and Greenberg
(2016), present an interesting paper on the transient receptor po-
tential (TRP) channels of schistosomes. They pointed out that only a
few classes of parasite helminth ion channels have been assessed
for their pharmacological properties or even their physiology. In
their paper they discuss the TRP channel superfamily which shares
a common core structure but which are widely diverse in their ion
selectivity. Bais and Greenberg (2016), also focus on one of these
channels, the SmTRPA channel which has a TRPV1-like pharma-
cology that could be exploited for therapeutic targeting. A genome-
based, single-nucleotide polymorphism (SNP) approach was used
by Mani et al. (2016), to examine sequence data of ion channels in
Diroﬁlaria immitis from eight different geographical locations: four
from macrocyclic lactone (ML) susceptible populations and four
from ML-loss of efﬁcacy (LOE) populations. They point out that the
SNPs identiﬁed may have effects on gene expression, function and
resistance selection. Two papers from the laboratory of Jonathan
Marchant (Chan et al., 2016a& b) on serotonergic G protein coupled
receptors (GPCRs) in ﬂatworms comment on their diversity of
ﬂatworm GPCRs for identifying ligands to treat parasitic ﬂatworm
infections. They illustrate a novel approach using a genetically
encoded cAMP biosensor to resolve the properties of an expressed
serotonergic GPCR (S7.1R). In the second of their papers, they
demonstrate the use of this approach and describe the pharma-
cology of an expressed myoexcitatory serotonergic receptor,
Sm.5HTRL.
An exciting presentation was the demonstration of a new
microﬂuidic platform for electrophysiological recordings from
hookworm and Ascaris suum larvae, (Weeks et al., 2016). This
platform is based on the Nematrix design that was originally
developed for C. elegans. The system has been used to examine the
electrical activity of the pumping pharynx of feeding A. suum L3s
and A. ceylanicum L4s and can be used to investigate effects of
anthelmintics and nematode feeding behavior.
An approach that is being used more frequently in drug design
was presented by the lab of Anne Lespine (David et al., 2016) who
described the in silico analysis of the C. elegans P-glycoprotein-1
transporter and its binding to anthelmintics. They observed that
avermectin anthelmintics have signiﬁcantly higher afﬁnity for Cel-
Pgp-1, due to the sugar substituent that binds to an area involving
H-bonds at Y771 of the inner chamber of the pump. Triclabenda-
zole, closantel and emodepside also bound to overlapping sites in
the inner chamber, suggesting that they could compete for Cel-Pgp-
1-mediated avermectin transport.
The possible repurposing of ﬂubendazole for ﬁlarial treatment
was illustrated by the Geary lab. O’Neill et al. (2016), reported an
RNAseq study of the effects of ﬂubendazole on adult male Brugiamalayi. The authors describe effects on genes associated with em-
bryo development and cuticlar components. Their data supports
the notion that ﬂubendazole acts predominantly on rapidly
dividing cells which may be of use in predicting efﬁcacious ﬂu-
bendazole treatment regimens.
The success of a meeting like ours depends on the ﬁnancial
support and time of many people, in addition to the formal orga-
nizers. We thank Dr. Deirdre Joy, program ofﬁcer at the NIAID for
her presentation; our Gold Sponsors: The Burroughs Wellcome
Fund and Bayer Animal Health; and our Silver Sponsors: Zoetis,
Elanco/Novartis Animal Health, New Biolabs and Nematrix. The
views expressed in this special issue do not imply endorsement of
commercial practices or organizations. We should also like to thank
Jennifer Vit of Iowa State University for handling the registration
and ﬁnance so efﬁciently and Melanie Abongwa and Drs. Alan
Robertson, Barbara Reaves and Saurabh Verma for their help ‘on the
ground’ in making sure things ran as smoothly as possible. Planning
for a third meeting in the series, provisionally to be held in Florida
in February 2018, has begun.
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